Get the Stockscreener App
1.15
0.44%
0.005
Opus Genetics Inc stock is traded at $1.15, with a volume of 85,309.
It is up +0.44% in the last 24 hours and down -5.74% over the past month.
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
See More
Previous Close:
$1.145
Open:
$1.13
24h Volume:
85,309
Relative Volume:
0.08
Market Cap:
$68.89M
Revenue:
$8.38M
Net Income/Loss:
$-27.19M
P/E Ratio:
-1.055
EPS:
-1.09
Net Cash Flow:
$-13.59M
1W Performance:
-4.17%
1M Performance:
-5.74%
6M Performance:
+4.55%
1Y Performance:
+0.00%
1-Day Range:
$1.124
$1.18
1-Week Range:
$1.10
$1.23
52-Week Range:
$0.65
$1.75
Opus Genetics Inc Stock (IRD) Company Profile
Name
Opus Genetics Inc
Sector
Industry
Phone
248-681-9815
Address
8 DAVIS DRIVE, DURHAM
Compare IRD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRD
Opus Genetics Inc
|
1.15 | 68.89M | 8.38M | -27.19M | -13.59M | -1.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Opus Genetics Inc Stock (IRD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-11-25 | Initiated | Craig Hallum | Buy |
| Nov-13-24 | Resumed | H.C. Wainwright | Buy |
Opus Genetics Inc Stock (IRD) Latest News
Night Vision Disturbances Market to Experience Notable Growth - openPR.com
Night Vision Disturbances Market to Experience Notable Growth by 2034, DelveInsight Predicts | Ocuphire Pharma, Viatris - The Globe and Mail
Opus Genetics’ OPGx-BEST1 cleared to enter clinic - BioWorld MedTech
FDA clears Opus Genetics' IND for BEST1 IRD gene therapy - Eyes On Eyecare
Opus Genetics announces FDA clearance of IND application for gene therapy candidate OPGx-BEST1 - Eyes On Eyecare
Promising Developments and Financial Stability Drive Buy Rating for Opus Genetics - TipRanks
Opus Genetics shares fall 4.17% intraday after FDA clearance of IND for OPGx-BEST1 gene therapy. - AInvest
Opus Genetics announces FDA clearance of IND application for OPGx-BEST1 - TipRanks
Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1 - GlobeNewswire
First Gene Therapy IND for Best Disease: Opus Genetics' BEST1 Treatment Advances to Clinical Trials - Stock Titan
What does recent volatility data suggest for Opus Genetics Inc.July 2025 Retail & Risk Adjusted Swing Trade Ideas - Newser
Is Opus Genetics Inc. still a buy after recent gainsWeekly Earnings Recap & Fast Exit and Entry Trade Guides - thegnnews.com
What high frequency data says about Opus Genetics Inc.Quarterly Earnings Summary & Reliable Price Breakout Signals - Newser
Opus Genetics reports Q2 EPS (12c) vs (30c) last year - MSN
Is Opus Genetics Inc. stock reversal real or fakePortfolio Update Summary & AI Forecasted Stock Moves - Newser
Earnings visualization tools for Opus Genetics Inc.July 2025 Levels & Real-Time Stock Movement Alerts - Newser
How Opus Genetics Inc. stock reacts to Fed policy changesQuarterly Profit Review & Verified Momentum Watchlists - Newser
Sentiment analysis tools applied to Opus Genetics Inc.Short Setup & Free Technical Pattern Based Buy Signals - Newser
Automated trading signals detected on Opus Genetics Inc.Quarterly Trade Summary & Real-Time Sentiment Analysis - Newser
What to do if you’re stuck in Opus Genetics Inc.2025 Market Outlook & Capital Efficient Trade Techniques - Newser
How to monitor Opus Genetics Inc. with trend dashboardsWeekly Risk Report & Risk Controlled Daily Plans - Newser
Can a trend reversal in Opus Genetics Inc. lead to recovery2025 Top Gainers & High Conviction Buy Zone Alerts - Newser
Opus Genetics, Inc. (NASDAQ:IRD) Just Reported Earnings, And Analysts Cut Their Target Price - ca.finance.yahoo.com
How liquid is Opus Genetics Inc. stockPortfolio Return Summary & High Yield Stock Recommendations - thegnnews.com
Volatility clustering patterns for Opus Genetics Inc.2025 Market Outlook & Fast Momentum Stock Entry Tips - Newser
Opus Genetics Inc. stock chart pattern explainedGold Moves & Safe Entry Zone Tips - Newser
Why Opus Genetics Inc. stock attracts strong analyst attentionJuly 2025 Macro Moves & Community Verified Swing Trade Signals - Newser
Foundation Fighting Blindness, Inc. Net Worth (2025) - GuruFocus
Will Opus Genetics Inc. outperform the marketQuarterly Profit Review & Capital Efficiency Focused Strategies - Newser
Price momentum metrics for Opus Genetics Inc. explainedAnalyst Upgrade & Breakout Confirmation Alerts - Newser
Trendlines Converge — Decision Point for Opus Genetics Inc.2025 AllTime Highs & Daily Stock Momentum Reports - beatles.ru
Opus Genetics: Promising Clinical Trials and Strategic Partnerships Drive Buy Rating - TipRanks
Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates - MSN
Park Ha Biological Technology Co., Ltd. shares fall 2.60% premarket after Opus Genetics reports positive clinical data and FDA designation. - AInvest
Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Product Pipeline Updates - VisionMonday.com
Opus Genetics (IRD): Can the Launch of Claude Opus 4.1 Catalyze a Path to Profitability? - AInvest
Opus Genetics earnings beat by $0.07, revenue fell short of estimates - Investing.com Canada
Opus Genetics Inc (IRD) Q2 2025 Earnings: EPS Beats Estimates at $(0.12), Revenue at $2.9 Million - GuruFocus
Opus Genetics: Navigating Financial Challenges with Promising Clinical Catalysts - AInvest
Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update - GlobeNewswire
Opus Genetics hits major milestones as eye disease treatments show promising results in multiple trials - Stock Titan
Using economic indicators to assess Opus Genetics Inc. potentialRSI Divergence and Support Breakout Analysis - Newser
Opus Genetics (IRD) to Release Earnings on Tuesday - Defense World
Opus Genetics IRD 2025Q2 Earnings Preview Upside Potential on New Claude Opus Model Release - AInvest
Custom watchlist performance reports with Opus Genetics Inc.High Return Strategy with Low Risk - Newser
Published on: 2025-08-08 22:54:28 - Newser
Opus Genetics Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
Opus Genetics Inc. stock trend outlook and recovery pathReal Time Alert System for Market Moves - Newser
Will Opus Genetics Inc. price bounce be sustainableTechnical Reversal Pattern Summary and Tracker - Newser
Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference - GlobeNewswire
Gene Therapy Leader Opus Genetics Showcases Retinal Disease Breakthroughs at Major Ophthalmology Conference - Stock Titan
Opus Genetics Inc Stock (IRD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Opus Genetics Inc Stock (IRD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| YERXA BENJAMIN R | President |
Nov 21 '24 |
Buy |
0.98 |
10,000 |
9,834 |
342,800 |
| Magrath George | Chief Executive Officer |
Nov 15 '24 |
Buy |
1.01 |
90,294 |
91,215 |
483,244 |
| Magrath George | Chief Executive Officer |
Nov 18 '24 |
Buy |
1.02 |
9,706 |
9,943 |
492,950 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):